The DOI matches its Crossref record.
Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
Abstract
OBJECTIVES: To determine the safety, pharmacokinetics, and activity of an anti-tumor necrosis factor (TNF)-alpha monoclonal antibody in severe sepsis. DESIGN: Open-label, prospective, phase II multicenter trial with escalating doses of a murine monoclonal antibody (CB0006). SETTING: Twelve academic medical center intensive care units in the United States and Europe. PATIENTS: Eighty patients with severe sepsis or septic shock who received standard supportive care and antimicrobial therapy in addition to the anti-TNF antibody. INTERVENTIONS: Patients were treated intravenously with one of four dosing regimens with CB0006: 0.1 mg/kg, 1.0 mg/kg, 10 mg/kg or two doses of 1 mg/kg 24 hrs apart. MEASUREMENTS AND MAIN RESULTS: The murine monoclonal anti-TNF antibody was well tolerated despite the development of anti-murine antibodies in 98% of patients. No survival benefit was found for the total study population, but patients with increased circulating TNF concentrations at study entry appeared to benefit by the high dose anti-TNF antibody treatment. Increased interleukin (IL)-6 levels predicted a fatal outcome (p = .003), but TNF levels were not found to be a prognostic indicator. TNF levels were higher (206.7 +/- 60.7 vs. 85.9 +/- 26.1 pg/mL; p < .001) and outcome was poor (41% vs. 71% survival; p = .007) in patients who were in shock at study entry when compared with septic patients not in shock. CONCLUSIONS: The murine anti-TNF-alpha monoclonal antibody CB0006 has proven to be safe in this clinical trial and may prove to be useful in septic patients with increased circulating TNF concentrations. Further studies are needed to determine efficacy and the ultimate clinical utility of this immunotherapeutic agent in sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein
Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M. H., & Benjamin, E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342603 · Cited by 1,241
Self-citationSir Isaac Newton, sepsis, SIRS, and CARS
Bone, R. C. (1996) · Critical Care Medicine · doi:10.1097/00003246-199607000-00010 · Cited by 989
Tumor necrosis factor in the heart
Meldrum, D. R. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.3.r577 · Cited by 746
Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An Updated View
Schulte, W., Bernhagen, J., & Bucala, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/165974 · Cited by 745
Garnacho-Montero, J., Garcia-Garmendia, J. L., Barrero-Almodovar, A., Jimenez-Jimenez, F. J., Perez-Paredes, C., & Ortiz-Leyba, C. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000098031.24329.10 · Cited by 718
Metadata
- Authors
- FISHER, C. J., OPAL, S. M., DHAINAUT, J.-F., STEPHENS, S., ZIMMERMAN, J. L., NIGHTINGALE, P., HARRIS, S. J., SCHEIN, R. M. H., PANACEK, E. A., VINCENT, J.-L., FOULKE, G. E., WARREN, E. L., GARRARD, C., PARK, G., BODMER, M. W., COHEN, J., DER LINDEN, C. V., CROSS, A. S., & SADOFF, J. C.
- Venue
- Critical Care Medicine
- Published
- 1993-03
- Volume
- 21
- Issue
- 3
- Pages
- 318-327
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W76818083
- Cited by
- 427
- References
- 0
- FWCI
- 46.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. https://app.cochat.ai/papers/10.1097/00003246-199303000-00006
- The paper
- FISHER, C. J., OPAL, S. M., DHAINAUT, J.-F., STEPHENS, S., ZIMMERMAN, J. L., NIGHTINGALE, P., HARRIS, S. J., SCHEIN, R. M. H., PANACEK, E. A., VINCENT, J.-L., FOULKE, G. E., WARREN, E. L., GARRARD, C., PARK, G., BODMER, M. W., COHEN, J., DER LINDEN, C. V., CROSS, A. S., & SADOFF, J. C. (1993). Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Critical Care Medicine. https://doi.org/10.1097/00003246-199303000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.